11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews Hagop Kantarjian MD from the MD Anderson Cancer Center in Houston about his latest findings on treating CML in patients who have the T315I mutation. He also discusses the feasibility of patients becoming pregnant while having tyrosine kinase inhibitor (TKI) treatment (among those who have achieved stability for at least two years); and talks about the decreased need for allogeneic transplant.[audio:https://www.audiomedica.com/podcasting/otbn/090419HagopKantarjianOTBN.mp3]
You may also like...
Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013 Gene Assay Predicts Which Patients Need Radiation After Prostatectomy 18 Apr, 2017 Acute promyelocytic leukaemia: arsenic better than chemotherapy to combine with retinoic acid? 18 Dec, 2012 Circulating free tumour DNA test could guide breast cancer therapy 3 Apr, 2013
- Previous story The Smartest Oncologist In The World?
- Next story Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014